DUBLIN--(BUSINESS WIRE)--The "Global Breast Cancer Screening Tests Market - Segmented by Type of Tests and Geography - Growth, Trends, and Forecast (2018 - 2023)" report has been added to ResearchAndMarkets.com's offering.
The global breast cancer screening tests market is expected to grow during the forecast period 2018-2023.
Breast cancer is the most common cancer in women, in both developed and less developed countries. According to WHO, it was estimated that over 508,000 women died in 2011, due to breast cancer worldwide.
Breast cancer incidence rates vary a great deal around the world. Generally, developed countries (such as the United States, England, and Australia) have higher rates than developing countries (such as Cambodia, Nepal, and Rwanda). There were 14.1 million new cancer cases, 8.2 million cancer deaths, and 32.6 million people were living with cancer in 2012, in the world over. As a result, increasing number of people are opting regular screening tests, which in turn is driving the global breast cancer screening market.
Furthermore, the increasing awareness about early detection of breast cancer and increasing government initiatives for breast cancer are also driving the market to grow.
Key Developments in the Market
- November 2017: Hologic, Inc. has provided all mammography systems for the Dutch Breast Cancer Screening Program in partnership with Tromp Medical.
- March 2017: Hologic presented its New Breast Cancer Screening and Interventional Solutions (Affirm prone breast biopsy system).
Key Topics Covered
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porter's Five Forces Analysis
6. Drivers, Restraints, Opportunities and Challenges Analysis (DROC)
6.1 Market Drivers
6.2 Market Restraints
6.4 Key Challenges
7. Market Segmentation
7.1 Segmentation by Tests
7.2 Segmentation by Geography
8. Competitive Landscape
8.1 Mergers and Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Product Launches
9. Key Players
9.1 A&G Pharmaceutical Inc.
9.2 Myriad Genetics
9.3 Agendia BV
9.4 Armune BioScience Inc.
9.5 Metabolomic Technologies Inc.
9.6 Roche Diagnostics Limited
9.7 Siemens Healthcare Diagnostics Inc.
9.8 Biocrates Life Sciences AG
9.9 Hologic Inc.
9.10 Quest Diagnostics Incorporated
10. Future of the Market
For more information about this report visit https://www.researchandmarkets.com/research/fn3z3m/breast_cancer?w=4